advanced search

INJECTION

LESSONS FROM MARKETED MEDICAL DEVICES TO ENHANCE CONNECTED DRUG DELIVERY
CONNECTIVITY
Fallyn Flaherty-Earp
Celanese
LESSONS FROM MARKETED MEDICAL DEVICES TO ENHANCE CONNECTED DRUG DELIVERY
Fallyn Flaherty-Earp looks at what medical device manufacturers can learn from connected devices already on the market and discusses the opportunities electronic inks can provide for the development of innovative therapies for the treatment of chronic diseases.
Interview with Arnaud Guillet & Fanny Sellier
INTERVIEW
Arnaud Guillet
Biocorp
Interview with Arnaud Guillet & Fanny Sellier
Arnaud Guillet and Fanny Sellier talk with Guy Furness about how Biocorp has become a key player in the field of connected drug delivery, discuss the current landscape for connectivity in drug delivery and update us on its two major parenteral products – Mallya and Injay – as well as looking forward to the launch of the company’s next generation of connected drug delivery solutions.
COLLABORATIVE INNOVATION IN CONNECTED AUTOINJECTORS: HIGH-IMPACT ADHERENCE SOLUTIONS
CONNECTIVITY
Chelsea Williams
SHL Medical
COLLABORATIVE INNOVATION IN CONNECTED AUTOINJECTORS: HIGH-IMPACT ADHERENCE SOLUTIONS
Chelsea Williams, Nils Weber and Gene Rhode Fuensalida Pantig discuss the potential of collaborative innovation in connected drug delivery when it comes to creating high-impact, low-touch adherence solutions.
COLD STORAGE AND CONTAINER CLOSURE INTEGRITY – DEMONSTRATED PERFORMANCE OF ETFE-COATED COMPONENTS
INJECTION
Sebastien Cordier
Aptar Pharma
COLD STORAGE AND CONTAINER CLOSURE INTEGRITY – DEMONSTRATED PERFORMANCE OF ETFE-COATED COMPONENTS
Sebastien Cordier; Benjamin Brocco; Estelle Verger and Arnaud Clausse discuss the results of a series of tests to demonstrate that PremiumCoat® can maintain closure integrity down to -80°C.
ENSURING PATIENT SAFETY AMIDST MEDICAL DEVICE REGULATION DELAYS WITH PMS
EXPERT VIEW
Timothy Bubb
ENSURING PATIENT SAFETY AMIDST MEDICAL DEVICE REGULATION DELAYS WITH PMS
Timothy Bubb discusses the five steps to setting up an effective post-market surveillance process.
INTEGRATED DRUG PRODUCT DEVELOPMENT AND MANUFACTURING
INDUSTRIALISATION
Dr Andrea Allmendinger
ten23 health
INTEGRATED DRUG PRODUCT DEVELOPMENT AND MANUFACTURING
Andrea Allmendinger; Michael Adler and Hanns-Christian Mahler highlight the importance of integrated drug product development, considering aspects such as formulation, device, container closure system, manufacturing processes and usability, as well as considering the quality target product profile and clinical phase-appropriate technical development strategy.
DESIGNING FOR USABILITY IN EMERGENCY-USE COMBINATION PRODUCTS
EXPERT VIEW
Thomas James
DESIGNING FOR USABILITY IN EMERGENCY-USE COMBINATION PRODUCTS
Thomas James highlights the importance of early user engagement, as well as continuous refinement of information and workflow design, for efficient development of drug-device combination products for emergency use.
HOW PATIENT & TREATMENT FACTORS SHAPE SUBCUTANEOUS DOSING PREFERENCES
INJECTION
Dr Andreas Schneider
Ypsomed
HOW PATIENT & TREATMENT FACTORS SHAPE SUBCUTANEOUS DOSING PREFERENCES
Andreas Schneider highlights the importance of understanding the drivers of dosing preferences when it comes to choosing the right injection device for patients. Specifically, the research summarised here studies whether and how patient characteristics and treatment attributes influence the decision to use prefilled handheld autoinjectors or large-volume wearable injectors.
TACKLING DESIGN CHALLENGES IN EMERGENCY-USE AUTOINJECTORS
EXPERT VIEW
John Burke
TACKLING DESIGN CHALLENGES IN EMERGENCY-USE AUTOINJECTORS
John Burke considers the challenges that manufacturers need to overcome when designing emergency-use autoinjectors.
HARNESSING HUMAN FACTORS IN CONNECTED DEVICE DEVELOPMENT
CONNECTIVITY
Finola Austin
Owen Mumford
HARNESSING HUMAN FACTORS IN CONNECTED DEVICE DEVELOPMENT
Finola Austin looks at the role human factors testing plays in the development of connected drug delivery devices.
ADDRESSING PEPTIDE THERAPEUTICS WITH A VERSATILE PEN PLATFORM
INJECTION
Cecile Gross
Nemera
ADDRESSING PEPTIDE THERAPEUTICS WITH A VERSATILE PEN PLATFORM
Cécile Gross and Mark Tunkel discuss the rising demand in peptide therapeutics and how Nemera’s PenVario pen injector platform, coupled with Nemera’s end-to-end service offering, has been designed to help pharma partners achieve success in this sector.
STRATEGIES FOR TEST METHOD VALIDATION OF DRUG DELIVERY PLATFORMS
EXPERT VIEW
Deepu Asok
STRATEGIES FOR TEST METHOD VALIDATION OF DRUG DELIVERY PLATFORMS
Deepu Asok discusses the importance of test method validation for drug-device combination product development and how a common mistake is to design the validation process for a specific device rather than to accommodate the potential variety of a device platform.
OXYCAPT: SUPERIOR PRIMARY CONTAINERS FOR BIOLOGICS AND GENE AND CELL THERAPIES
INJECTION
Tomohiro Suzuki
Mitsubishi Gas Chemical
OXYCAPT: SUPERIOR PRIMARY CONTAINERS FOR BIOLOGICS AND GENE AND CELL THERAPIES
Tomohiro Suzuki reviews the advantages that OXYCAPT™, Mitsubishi Gas Chemical's multilayer material for vials, offers to biologics and gene and cell therapies, and discusses the results of recent tests into low-temperature storage and dimethyl sulfoxide resistance.
MITIGATING CONTAINER CLOSURE INTEGRITY CHALLENGES FOR INJECTABLES
EXPERT VIEW
Eugene Polini
MITIGATING CONTAINER CLOSURE INTEGRITY CHALLENGES FOR INJECTABLES
Eugene Polini discusses the importance of container closure for the parenteral drug market, including some of the consequences of compromised container closure and what steps manufacturers can take to ensure that primary packaging systems remain sealed for a product’s entire shelf life.
DESIGNING SUSTAINABILITY INTO PHARMACEUTICAL DEVICES
EXPERT VIEW
Will Davies
DESIGNING SUSTAINABILITY INTO PHARMACEUTICAL DEVICES
Will Davies discusses in detail how to address the challenges of designing sustainability into pharmaceutical devices.
SUSTAINABILITY IN DRUG DELIVERY: HOW DO WE GET THERE?
EXPERT VIEW
Tim Wooller
SUSTAINABILITY IN DRUG DELIVERY: HOW DO WE GET THERE?
Tim Wooller discusses the urgent need to transition away from disposable models of drug delivery device design and move towards reusables, providing insights into the reasons why and the methods by which this can be achieved.
OPTIMISING MICROLITRE DOSING: CASE STUDY WITH INTRAVITREAL INJECTION
OCULAR
Yuki Takeuchi
Terumo Medical Care Solutions
OPTIMISING MICROLITRE DOSING: CASE STUDY WITH INTRAVITREAL INJECTION
Yuki Takeuchi and Richard Whelton discuss the challenges of delivering intravitreal injections and how the combination of Terumo’s PLAJEX™ prefillable syringes with Congruence’s Microlitre Dosing Syringe system is able to address them.
INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE
OCULAR
Dr Andrea Allmendinger
ten23 health
INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE
Andrea Allmendinger and Hanns-Christian Mahler highlight the technical challenges of intravitreal administration and considerations from the ophthalmologist’s and patient’s perspectives.
PATIENT-CENTRIC DESIGN CAN BE A FASTER PATH TO MARKET
INJECTION
Dr Brent Buchine
Windgap Medical
PATIENT-CENTRIC DESIGN CAN BE A FASTER PATH TO MARKET
Brent Buchine considers a faster path to market for automated and easy-to-use reconstitution devices through simplification of the delivery systems.
AN INTUITIVE ALL-IN-ONE AUTOINJECTOR: EMBEDDED MIXING & INJECTION TECHNOLOGIES SIMPLIFY DAY-TO-DAY LIFE
INJECTION
Benjamin Morel
Eveon
AN INTUITIVE ALL-IN-ONE AUTOINJECTOR: EMBEDDED MIXING & INJECTION TECHNOLOGIES SIMPLIFY DAY-TO-DAY LIFE
Benjamin Morel and Gladys Corrons-Bouis, discuss the challenges faced by the injectable drug delivery industry and present EVEON’s solution – the INTUITY® Ject MX platform.
NEXT-GENERATION AUTOINJECTOR PLATFORM FOR HIGH-DOSE DRUGS
INJECTION
Richard Whelton
Congruence Medical Solutions
NEXT-GENERATION AUTOINJECTOR PLATFORM FOR HIGH-DOSE DRUGS
Richard Whelton introduces the new Congruence Autoinjector, a next-generation disposable autoinjector platform, which leverages a compressed-gas power source and has significant advantages over currently available legacy devices, including the ability to deliver higher viscosity and larger volume drugs, easier customisation and enhanced usability that addresses well-known user errors.
OPPORTUNITIES FOR INNOVATION WITH BIOSIMILARS
PREFILLED SYRINGES
Dr Iain Simpson
Phillips Medisize
OPPORTUNITIES FOR INNOVATION WITH BIOSIMILARS
Iain Simpson and George Spooner investigate the use of drug delivery systems that support self-administration of biologic drugs, and specifically biosimilars, for the treatment of chronic diseases. This article is based on research conducted by both authors as part of the MPhil in Therapeutic Sciences at the University of Cambridge (UK) and supported by Phillips-Medisize.
Pro-Tects – A NOVEL SOLUTION TO THE CHALLENGE OF BIOLOGIC INSTABILITY
INJECTION
Dr Shane Smith
Glycome BioPharma
Pro-Tects – A NOVEL SOLUTION TO THE CHALLENGE OF BIOLOGIC INSTABILITY
Shane Smith, Eoin Scanlan and Paula Colavita discusses the difficulty inherent in developing parenteral biologic products due to the challenge of creating a stable formulation in the face of surface-mediated protein aggregation and introduces Pro-Tects – Glycome’s patented surface-treatment technology platform that offers a solution to this critical issue without introducing further development challenges.
ENABLING LARGE-VOLUME, HIGH-DOSE SUBCUTANEOUS AUTOINJECTIONS WITH CARTRIDGE-BASED TECHNOLOGIES
INJECTION
Michael McGowan
SHL Medical
ENABLING LARGE-VOLUME, HIGH-DOSE SUBCUTANEOUS AUTOINJECTIONS WITH CARTRIDGE-BASED TECHNOLOGIES
Michael McGowan, examines the emerging interest in autoinjectors that are capable of delivering higher injection volumes into the subcutaneous space and considers the potential benefits of SHL Medical’s cartridge-based 3 and 5 mL Maggie® autoinjectors.
Top